RPRX
Royalty Pharma plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Royalty Pharma plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Royalty Pharma plc
67.34
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Morgan StanleyMorgan Stanley | $2.4B | 11.68% | −1.47% | |
| 2 | Capital International InvestorsCapital International Investors | $2.0B | 9.59% | +0.77% | |
| 3 | BlackRockBlackRockindex-like | $1.6B | 7.57% | +7.43% | |
| 4 | FMRFMR | $1.4B | 6.67% | −2.54% | |
| 5 | State StreetState Streetindex-like | $691.8M | 3.36% | +12.27% | |
| 6 | T. Rowe Price AssociatesT. Rowe Price | $627.6M | 3.04% | +478.70% | |
| 7 | SwedbankSwedbank | $601.4M | 2.92% | −7.42% | |
| 8 | Baillie GiffordBaillie Gifford | $561.6M | 2.72% | −38.01% | |
| 9 | Capital World InvestorsCapital World Investors | $533.6M | 2.59% | +18.42% | |
| 10 | Geode Capital ManagementGeodeindex-like | $450.6M | 2.19% | +2.39% | |
| 11 | Caledonia (Private) Investments PtyCaledonia (Private) Investments Pty | $323.9M | 1.57% | −19.43% | |
| 12 | Norges BankNorges Bankindex-like | $299.2M | 1.45% | — | |
| 13 | Vanguard Capital ManagementVanguardindex-like | $270.6M | 1.31% | +6.50% | |
| 14 | Northern TrustNorthern Trustindex-like | $264.6M | 1.28% | +23.90% | |
| 15 | Royal London Asset ManagementRoyal London | $242.2M | 1.17% | +13.42% | |
| 16 | AQR Capital ManagementAQR | $241.4M | 1.17% | +13.84% | |
| 17 | InvescoInvesco | $237.3M | 1.15% | +12.80% | |
| 18 | Bank of AmericaBank of America | $232.7M | 1.13% | +18.70% | |
| 19 | Legal & General GroupLegal & General | $213.1M | 1.03% | +13.01% | |
| 20 | AmundiAmundi | $208.8M | 1.01% | +20.56% | |
| 21 | Victory Capital ManagementVictory | $206.5M | 1.00% | −4.43% | |
| 22 | Patient Capital ManagementPatient | $201.8M | 0.98% | −1.23% | |
| 23 | UBS GroupUBS | $176.2M | 0.85% | +73.45% | |
| 24 | Charles Schwab Investment ManagementCharles Schwabindex-like | $172.9M | 0.84% | +1.84% | |
| 25 | Two Sigma InvestmentsTwo Sigma | $163.7M | 0.79% | +29.70% |
648 managers report $20.6B of Royalty Pharma on form 13F for the quarter ended Jun 30 '26. 44 of them hold 80% of it; Morgan Stanley is largest at 11.68%.
Linked news
Expected move
Inputs8Q avg ±3.2%·×0.41·cheap
straddle ±5.4%
spot 67.18exp Nov 20ATM strike 67.5ATM straddle 4.28IV 33%